VT-464, Drug in Development with PCCTC, Fast Tracked by FDA
January 8, 2016 | Press Releases
Innocrin’s CYP17 lyase inhibitor seviteronel (VT-464), currently in PCCTC-led early phase clinical development, is granted fast track designation for patients with castration-resistant prostate cancer (CRPC) by the FDA.
Committed to world-class science!
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.